Adamas Pharmaceuticals, Inc.

Adamas Pharmaceuticals, Inc.

Adamas Pharmaceuticals, Inc.

Overview
Date Founded

2000

Headquarters

2200 Powell Street,Suite 220,Emeryville, CA 94608

Type of Company

Public

Employees (Worldwide)

138

Industries

Pharmaceuticals
Biotechnology
Hospitals & Patient Services

Company Description

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.

Contact Data
Trying to get in touch with decision makers at Adamas Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Chief Financial Officer & Chief Accounting Officer

Chief Commercial Officer

Chief Medical Officer

Head of Corporate Development, Strategy, Portfolio Planning & Alliance Management

Head of Corporate Communications, Patient Advocacy & Engagement

Head of Human Resources

Vice President, Clinical Research

Chief Commercial Officer

Head of Patient Access

Board of Directors

Former Principal at McKinsey & Co., Inc.

General Counsel & Chief Compliance Officer at Cargill, Inc.

Chief Executive Officer & Executive Director at The Jed Foundation

Former Chief Executive Officer at Paratek Pharmaceuticals Inc.

Managing Partner at Mohr Davidow Ventures

Professional at Chimerix, Inc.

Chief Executive Officer at Adamas Pharmaceuticals, Inc.

Senior Vice President, Head of Clinical Development at ACADIA Pharmaceuticals, Inc.

Paths to Adamas Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
Adamas Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden

Armistice Capital is a global, long/short, value-oriented and event-driven hedge fund firm which focuses primarily on the health care and consumer sectors. They invest predominantly in equities and can be opportunistic across the capital structure. The firm seeks to maximize the opportunity set of investment candidates allowing for the selection of unique, concentrated bets to generate uncorrelated returns. They maintain significant position and portfolio level hedges in an effort to mitigate basis and market risks. Armistice Capital employs a bottom-up analysis, assessing all components of the company’s capital structure and aims to take larger positions where the greatest potential risk adjusted return exists. Armistice Capital’s Domestic Fund and the Offshore Fund, through their investments in the Master Fund, seek to achieve long-term capital appreciation by employing an opportunistic global long/short strategy for investing in distressed debt, value equities and event equities. In all of its investing activities, the Funds will seek to emphasize capital preservation and will seek to mitigate risk through various hedging strategies at both the position and portfolio levels.

Details Hidden

Stonepine Capital Management focuses primarily, but not exclusively, on equity and equity-related securities in US publicly healthcare companies. The firm seeks to invest in companies whose valuations reflect a material discount to their fundamental value in the healthcare space. Stonepine typically prefers to invest in companies at a price reflecting a discount to current commercial and financial assets alone.The Stonepine Funds’ investment objective is to achieve superior absolute returns while preserving capital. They have formed Special Purpose Vehicles (SPVs) whose investment objective may differ because these investments tend to be more concentrated than the Stonepine Funds. Stonepine seeks to achieve their investment objective primarily by investing assets in publicly traded healthcare companies. Stonepine's investment focus is companies with commercial stage products generating sustainable revenue and companies with substantial financial assets (such as cash and royalty income streams).

Details Hidden

AIGH Capital Management LLC is an independent asset management firm headquartered in Baltimore, Maryland. Founded in 2011, the firm provides investment management services to individual and institutional clients.

Recent Transactions
Details Hidden

Adamas Pharmaceuticals, Inc. issued USD Common Stock

Details Hidden

Adamas Pharmaceuticals, Inc. issued USD Common Stock

Details Hidden

Adamas Pharmaceuticals, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Transaction Advisors
Auditor

Advised onAdamas Pharmaceuticals, Inc. issued USD Common Stock

Escrow Agent

Advised onAdamas Pharmaceuticals, Inc. issued USD Common Stock

Underwriter

Advised onAdamas Pharmaceuticals, Inc. issued USD Common Stock

Legal Advisor

Advised onAdamas Pharmaceuticals, Inc. issued USD Common Stock

Legal Advisor

Advised onAdamas Pharmaceuticals, Inc. issued USD Common Stock

Managing Director

Advised onAdamas Pharmaceuticals, Inc. issued USD Common Stock

Advisors & Consultants
Scientific Advisor

Clinical Professor of Medicine at UCSF School of Medicine

Consultant

Former Chief Financial Officer & Vice President-Finance at Cerus Corp.

Advisor

Managing Partner at Mohr Davidow Ventures

Clients

Walgreens Boots Alliance, Inc. engages in the provision of drug store services. It operates through the following segments: Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale. The Retail Pharmacy USA segment consists of the Walgreens business, which includes the operation of retail drugstores, health and wellness services, and mail and central specialty pharmacy services. The Retail Pharmacy International segment consists of pharmacy-led health and beauty retail businesses and optical practices. The Pharmaceutical Wholesale segment consists of the Alliance Healthcare pharmaceutical wholesaling and distribution businesses and an equity method investment in AmerisourceBergen. The company was founded in 1901 and is headquartered in Deerfield, IL.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the discovery, development, manufacture and sale of a line of proprietary pharmaceutical products. It is focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C and human immunodeficiency virus; neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. The company was founded on 2013 and is headquartered in North Chicago, IL.

Key Stats and Financials As of 2020
Market Capitalization
$231M
Total Enterprise Value
$178M
Earnings Per Share
$-2.03
Revenue
$74.5M
EBITDAMargin
-58.17%
Enterprise Value / Sales
2.38x
TEVNet Income
-3.09x
Debt TEV
0.78x
Total Equity
$-50M
EBITDA
$-43.3M
Total Debt
$138M
Net Profit
$-57.4M
Three Year Compounded Annual Growth Rate Of Revenue
407.1%
Non-Profit Donations & Grants
$5,500 - $15K
2018
$25K - $100K
2017
$1,000 - $4,999
2016
Investors
Details Hidden

Professor, Department of Molecular Medicine at The Scripps Research Institute - California

Details Hidden

OTPPB is an active, global investor that manages investment portfolio for the benefit of present and future plan members and their survivors. The firm seeks to achieve superior returns and manage related risks to ensure the long-term sustainability of the pension plan. With board oversight, the plan's management manages both the policy and asset mix together under their expanded OneTeachers' total-fund strategy. Management determines exposure to each asset class within ranges approved by the board. Their asset mix includes equities, fixed income, inflation sensitive assets and real assets (real estate, infrastructure and real-rate products), and they make sure that they maintain broad diversification among their assets. OTPPB also uses absolute return strategies, which enable them to earn positive returns that are uncorrelated to other asset groups. The firm employs these strategies internally to capitalize on market inefficiencies.

Details Hidden

Director, Institute for Transformative Molecular Medicine at University Hospitals of Cleveland

Suppliers
Catalent, Inc. Other Business & Consulting Services | Somerset, NJ

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets, and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy; formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges; and analytical development and testing services for large molecules. The Oral and Speciality Delivery segment consists of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment involves packaging, storage, distribution, and inventory management for drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.

PMC Global, Inc. Accounting & Financial Services | Sun Valley, CA

PMC Global, Inc. manufactures electronic products. It also manufactures plastics, chemicals, health and beauty, food, and cutlery products. The company was founded by Philip E. Kamins in 1971 and is headquartered in Sun Valley, CA.

Model N, Inc. IT Consulting & Services | Redwood City, CA

Model N, Inc. engages in the provision of revenue management cloud solutions for the life science and technology industries. Its solutions include two complementary suites of software applications: Revenue Management Enterprise and Revenue Management Intelligence. The Revenue Management Enterprise suite serves as the system of record for and automates the execution of revenue management processes such as pricing, contracting and incentive & rebate management. The Revenue Management Intelligence suite provides analytical insights to define and optimize revenue management strategies. The company was founded by Yarden Malka, Zack Rinat and Ali Tore on December 14, 1999 and is headquartered in San Mateo, CA.

Competitors
Bausch Health Cos., Inc. Pharmaceuticals - Laval, Canada

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Acorda Therapeutics, Inc. Pharmaceuticals - Ardsley, NY

Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its products include Inbrija (levodopa inhalation powder), Ampyra (dalfampridine), Fampyra (fampridine) and Selincro (nalmefene). The firm's also offers Research and Development Programs like ARCUS for acute migraine, Cimaglermin alfa and rHIgM22. The company was founded by Ronald Cohen in 1995 and is headquartered in Ardsley, NY.

GlaxoSmithKline Plc Pharmaceuticals - Brentford, Gbr

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Adamas Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Adamas Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Adamas Pharmaceuticals, Inc..